Vimarsana
Biggest News Aggregation in the World

Page 10 - End Results Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from End Results Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In End Results Program Today - Breaking & Trending Today

RedHill Announces FDA sNDA Approval for Talicia® - Vimarsana News

RedHill Announces FDA sNDA Approval for Talicia®

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the U.S. Food and Drug...

Carlton Pearson hospitalized for sepsis, battling cancer | Church & Ministries News - Vimarsana News

Carlton Pearson hospitalized for sepsis, battling cancer | Church & Ministries News

Bishop Carlton Pearson, an affiliate minister at All Souls Unitarian Church, who was once one of the most sought-after Pentecostal speakers in America before he lost his megachurch in Tulsa, Oklahoma, 20 years ago for declaring there is no Hell, says he was recently brought to “death’s door,” battling illnesses related to cancer.

Cancer Rates Are Mysteriously Increasing in Younger People - Vimarsana News

Cancer Rates Are Mysteriously Increasing in Younger People

Research is showing that cancer rates are increasing within the younger population of the U.S., specifically in the, “under 50” age group..

FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC) - Vimarsana News

FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)

/PRNewswire/ -- Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved LONSURF®...

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab - Astellas Pharma (OTC:ALPMY) - Vimarsana News

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab - Astellas Pharma (OTC:ALPMY)

TOKYO, July 31, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products